XML 51 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation Arrangements (Tables)
12 Months Ended
Dec. 31, 2012
Stock-Based Compensation Arrangements  
Schedule of stock based compensation expense

 

 

 

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

Year ended
December 31,
2012

 

 

 

$000

 

$000

 

$000

 

Research and development

 

351

 

171

 

71

 

General and administrative

 

1,344

 

669

 

266

 

(Loss) income from discontinued operations, net of tax

 

51

 

42

 

43

 

Stock-based compensation costs before income taxes

 

1,746

 

882

 

380

 

Schedule of stock option activity

 

 

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value

 

Options outstanding at December 31, 2010

 

498,562

 

$

27.72

 

7.22

 

$

938

 

Granted

 

28,500

 

$

10.64

 

 

 

 

 

Exercised

 

(948

)

$

2.87

 

 

 

 

 

Cancelled/forfeited

 

(23,865

)

$

40.53

 

 

 

 

 

Options outstanding at December 31, 2011

 

502,249

 

$

26.11

 

6.44

 

$

140

 

Granted

 

33,571

 

$

3.29

 

 

 

 

 

Exercised

 

(33,351

)

$

3.09

 

 

 

 

 

Cancelled/forfeited

 

(39,446

)

$

20.21

 

 

 

 

 

Options outstanding at December 31, 2012

 

463,023

 

$

26.61

 

5.58

 

347

 

Unvested at December 31, 2011

 

69,781

 

$

8.83

 

8.44

 

68

 

Vested and exercisable at December 31, 2012

 

393,242

 

$

29.77

 

5.07

 

279

 

Schedule of information about options outstanding

The following table summarizes information about options outstanding at December 31, 2012:

 

Exercise price ($)

 

Number
outstanding

 

Weighted
Average
remaining
contractual
life

 

Number
exercisable

 

  2.03 —   13.86

 

196,078

 

7.24

 

133,108

 

15.05 —   34.62

 

44,618

 

6.11

 

37,807

 

36.63 —   40.67

 

72,581

 

4.81

 

72,581

 

43.75 —   48.65

 

123,353

 

3.56

 

123,353

 

54.60 — 105.00

 

26,393

 

3.88

 

26,393

 

 

 

463,023

 

 

 

393,242

 

Schedule of assumptions for stock option grants to employees and directors

 

 

 

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

Year ended
December 31,
2012

 

Expected term (years)

 

5 — 6

 

5 — 6

 

6

 

Risk free interest rate

 

1.64 — 2.96%

 

1.47 — 2.29%

 

0.95%

 

Volatility

 

90 — 102%

 

93 — 99%

 

98%

 

Expected dividend yield over expected term

 

0.00%

 

0.00%

 

0.00%

 

Resulting weighted average grant date fair value

 

$9.80

 

$8.05

 

$2.52

 

Schedule of restricted stock activity

 

 

 

 

Restricted
Stock

 

Weighted Average
Grant
Date Value Per Share

 

Non-vested at December 31, 2010

 

3,418

 

$

3.08

 

Vested

 

(1,786

)

$

3.08

 

Non-vested at December 31, 2011

 

1,632

 

$

3.08

 

Vested

 

(1,632

)

$

3.08

 

Non-vested at December 31, 2012

 

 

$

 

Schedule of restricted stock units activity

 

 

 

Restricted Stock
Units

 

Weighted Average
Grant
Date Value Per Share

 

Non-vested at December 31, 2010

 

5,142

 

$

3.08

 

Granted

 

34,000

 

$

5.81

 

Vested

 

(2,679

)

$

3.08

 

Non-vested at December 31, 2011

 

36,463

 

$

5.60

 

Granted

 

12,281

 

$

3.85

 

Forfeited

 

(6,904

)

$

4.99

 

Vested

 

(2,463

)

$

3.08

 

Non-vested at December 31, 2012

 

39,377

 

$

5.34